2026-05-05 20:02:12 UTC / 路透社
作者：帕德马纳班·安南坦
2026年5月5日 世界协调时晚上8:02 更新于1小时前
节点运行失败
2020年8月29日，美国马里兰州怀特奥克市美国食品药品监督管理局（FDA）总部外的标识牌。路透社/安德鲁·凯利/资料图
美国食品药品监督管理局
葛兰素史克公司
莫德纳公司
显示更多企业
5月5日（路透社）——美国卫生与公众服务部发言人表示，美国食品药品监督管理局官员叫停了多篇支持广泛使用的新冠疫苗和带状疱疹疫苗安全性的研究论文发表。
负责监管FDA的美国卫生与公众服务部发言人安德鲁·尼克松称，这些研究被撤回是因为其结论存在问题。
用晨间最新法律新闻开启你的一天，由《每日案卷》新闻简报直接发送至你的收件箱。点击此处注册。
广告 · 滚动继续
“这些研究被撤回是因为作者得出的宽泛结论并未得到基础数据的支持。FDA此举旨在保护其科学流程的严谨性，确保与该机构相关的任何工作都能达到其高标准，”他在给路透社的一封电子邮件中说道。
这些研究的撤回是这位卫生监管机构和政府限制疫苗获取的最新举措，反映了美国卫生部长小罗伯特·F·肯尼迪任内出台的更广泛政策变化。肯尼迪一直是疫苗的尖锐批评者。
在肯尼迪的任期内，特朗普政府大幅削减了疫苗研究资金，并对疫苗的安全性和有效性提出质疑，肯尼迪还对联邦卫生机构进行了全面改革。
广告 · 滚动继续
去年8月，美国卫生与公众服务部表示将逐步停止近5亿美元的mRNA疫苗开发资金，取消了由政府资助的资助机构生物医学高级研究与发展局（BARDA）监管的22个联邦项目。
去年6月，在肯尼迪的支持下，美国疾病控制与预防中心的一个专家小组投票决定从流感疫苗中移除含汞防腐剂硫柳汞，尽管长期以来有临床证据证明其安全性。
英国制药商葛兰素史克销售的欣安立适（Shingrix）是一款带状疱疹疫苗，带状疱疹是一种会引发水疱和皮疹的疼痛性病毒感染，而辉瑞和莫德纳是新冠疫苗的主要生产商。
《纽约时报》最先报道了这一举措。
帕德马纳班·安南坦在班加罗尔报道；塔西姆·扎希德编辑
我们的准则：路透社信任原则。
US FDA blocked publication of COVID, shingles vaccine safety studies
2026-05-05 20:02:12 UTC / Reuters
By Padmanabhan Ananthan
May 5, 2026 8:02 PM UTC Updated 1 hour ago
节点运行失败
Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo
U.S. Food and Drug Administration
GSK plc
Moderna Inc
Show more companies
May 5 (Reuters) – Officials at the U.S. Food and Drug Administration blocked the publication of several studies supporting the safety of widely used vaccines against COVID-19 and shingles, a Department of Health and Human Services spokesperson said.
Andrew Nixon, a spokesman for the Department of Health and Human Services, which oversees the FDA, said the studies were pulled over concerns about their conclusions.
Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.
Advertisement · Scroll to continue
“The studies were withdrawn because the authors drew broad conclusions that were not supported by the underlying data. The FDA acted to protect the integrity of its scientific process and ensure that any work associated with the agency meets its high standards,” he said in an email to Reuters.
The withdrawal of these studies is the latest attempt by the health regulator and the administration to limit access to vaccines, reflecting broader policy changes under U.S. Health Secretary Robert F. Kennedy Jr., a staunch critic of vaccines.
The Trump administration has sharply reduced funding for vaccine research and raised questions about vaccine safety and effectiveness under the tenure of Kennedy, who has introduced sweeping changes across federal health agencies.
Advertisement · Scroll to continue
In August last year, the U.S. Department of Health and Human Services said it would wind down nearly $500 million in mRNA vaccine development, cancelling 22 federal projects overseen by the Biomedical Advanced Research and Development Authority (BARDA), a government-backed funding body.
Last June, a Centers for Disease Control and Prevention panel backed by Kennedy voted to remove mercury-based preservative thimerosal from flu shots, despite long-standing clinical evidence of its safety.
British drugmaker GSK markets Shingrix, a vaccine for shingles, a painful viral infection that causes blisters and rashes, while Pfizer and Moderna are the leading makers of COVID-19 vaccines.
The New York Times first reported the move.
Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Tasim Zahid
Our Standards: The Thomson Reuters Trust Principles.
发表回复